EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How much prophylaxis is enough in haemophilia?

Manuel Carcao iD, Veena Selvaratnam, Jan Blatny iD

Haemophilia · 2024-04 · 30 (S3) · 86-94

DOI: 10.1111/hae.14964 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Haemophilia, online erschienen am 24.03.2024. Verfasst von Manuel Carcao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology/Oncology; Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prophylaxis has become standard of care for all persons with haemophilia (PWH) with a severe phenotype. However, ‘standard prophylaxis’ with either factor or non‐factor therapies (currently only emicizumab available) is prohibitively expensive for much of the world. We sought to address the question of ‘How much prophylaxis is enough?’ and ‘Can it be individualized?’ and specifically ‘Can emicizumab be individualized?’.

Methods

We reviewed the literature on prophylaxis in haemophilia since its inception in the 1950s to the present, the development of more and less intense factor prophylaxis regimens and their outcomes and additionally the published outcomes of prophylaxis with low dose emicizumab.

Results

What these experiences collectively show is that low dose emicizumab does result in significant benefits to patients whilst being much less expensive than a “one size fits all” emicizumab prophylaxis approach. We also took note that some non‐factor therapies still in development are individualized given that high doses of these can potentially put patients at risk.

Conclusions

Prophylaxis is now clearly accepted as standard of care for PWH with a severe phenotype but now in a very short time a large assortment of different treatment options for prophylaxis have become/are becoming available and the haemophilia community will need to determine how to best use these recognizing that no ‘one treatment fits all’.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, BispecificHumansFactor VIII

Stichwörter der Autor:innen

haemophiliaindividualizationlow dose emicizumaboutcomesprophylaxis

Substanzen

Antibodies, BispecificFactor VIII

Autor:innen und Institutionen

  • Division of Haematology/Oncology; Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Hematology Department, Ampang Hospital, Ampang, Selangor, Malaysia.
  • Hospital Bory, Bratislava, Slovakia and Masaryk University, Brno, Czech Republic.

ORCID-Profile: Manuel Carcao, Jan Blatny

Zitieren

APA

Carcao, M., Selvaratnam, V., & Blatny, J. (2024). How much prophylaxis is enough in haemophilia?. Haemophilia, 30(S3), 86-94. https://doi.org/10.1111/hae.14964

Vancouver

Carcao M, Selvaratnam V, Blatny J. How much prophylaxis is enough in haemophilia?. Haemophilia. 2024;30(S3):86-94. doi:10.1111/hae.14964

BibTeX
@article{Carcao2024,
  author = {Carcao, Manuel and Selvaratnam, Veena and Blatny, Jan},
  title = {How much prophylaxis is enough in haemophilia?},
  journal = {Haemophilia},
  year = {2024},
  volume = {30},
  number = {S3},
  pages = {86--94},
  doi = {10.1111/hae.14964}
}
Kostenlos starten →